Bayer Ponders Road Less Traveled And Trip Savings In Pandemic
Travel Costs Halved From €600-700m Per Year Before COVID
Like most CEOs in pharma, Bayer chief Werner Baumann was constantly on the move but "since the middle to the end of the first quarter last year, I haven't traveled at all."
You may also be interested in...
The emergence and rapid spread of the Omicron variant has kept COVID-19 firmly in the headlines but the biopharma industry has had plenty on its plate on top of tackling the pandemic. Scrip has taken a look back at five of the biggest non-COVID-19 story themes of 2021 in no particular order.
In Part 2 of Scrip’s roundtable, execs from Athira, Cartesian, Cyclacel, Tonix and VOZ Advisors discuss how the pandemic brought in new investors and triggered strategic shifts for the biopharma industry.
Europe does not have a pricing environment that rewards innovation which improves outcomes for patients, according to Vas Narasimhan, although Germany seems to be the best of a bad bunch.